Drugs / TGW101-ADC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06959706 | May 2025 → Sep 2026 overdue | cancer | Tagworks Pharmaceuticals BV | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGW101-ADC | “TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered...” NCT06959706 ↗ |
| Modality | Other / unclassified | “chemically cleavable diabody drug conjugate” NCT06959706 ↗ |
| Route | Intravenous | “TGW101-anti-drug conjugate (ADC) will be administered via intravenous (IV) infusion” NCT06959706 ↗ |